Evaluation of lifespan in AN69ST with two different heparinization strategies
- Conditions
- Acute renal failure/ fluid overloadUrological and Genital DiseasesAcute renal failure
- Registration Number
- ISRCTN01121161
- Lead Sponsor
- Gambro Lundia AB (Sweden)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 44
1. Patients requiring continuous renal replacement therapies (CRRT)
2. Aged 18 and over
3. Patients weighing 30-120 kg
4. Patients having signed a written consent to participate in the study
1. History of heparin antibodies or heparin-induces thrombocytopenia
2. Known hypertensive to any dialysis membrane
3. Current enrolment in another trial which could impact the successful completion of this study
4. Patients under guardianship
5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients can eventually be included in a later more stable phase
6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study
7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices
8. Patients with active bleeding who does not require heparinization
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting.
- Secondary Outcome Measures
Name Time Method Adverse events, monitored for up to 24 days of treatment